Vanguard Capital Management
KAPA

Vanguard Capital Management’s Kairos Pharma KAPA Stock Holding History

Vanguard Capital Management’s Portfolio KAPA Stock Details KAPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89K Hold
231,878
– – ﹤0.01% 3886
2026
Q1 		$130K Buy
+231,878
New +$155K ﹤0.01% 3841

Other funds holding KAPA

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
SFG
SevenBridge Financial Group Harrisburg, Pennsylvania $680M AUM 30.75% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $14.6B AUM 22.78% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Vanguard Capital Management's KAPA Position: Q2 2026 in Review

Vanguard Capital Management held its Kairos Pharma (KAPA) position steady in Q2 2026 at 231,878 shares worth $89K. The position accounts for ﹤0.01% of the portfolio, ranked #3886.

Vanguard Capital Management first reported a position in KAPA in Q1 2026 and has held it in 2 quarters since. The position peaked at $130K in Q1 2026. 14 funds tracked by Wall St. Rank hold KAPA as of Q2 2026.

  • Vanguard Capital Management held 231,878 shares of Kairos Pharma worth $89K as of Q2 2026.
  • Vanguard Capital Management left its Kairos Pharma share count unchanged in Q2 2026.
  • Kairos Pharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3886 holding.
  • Vanguard Capital Management first reported a position in Kairos Pharma in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Kairos Pharma position peaked at $130K in Q1 2026.
  • 14 funds tracked by Wall St. Rank held Kairos Pharma as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.